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LMO2 was discovered via chromosomal translocations in T-cell leukaemia and shown normally to be
essential for haematopoiesis. LMO2 ismade up of two LIM only domains (thus it is a LIM-only protein) and
forms a bridge in a multi-protein complex. We have studied the mechanism of formation of this complex
using a single domain antibody fragment that inhibits LMO2 by sequestering it in a non-functional form.
The crystal structure of LMO2 with this antibody fragment has been solved revealing a conformational
difference in the positioning and angle between the two LIM domains compared with its normal binding.
This contortion occurs by bending at a central helical region of LMO2. This is a unique mechanism for
inhibiting an intracellular protein function and the structural contusion implies a model in which newly
synthesized, intrinsically disordered LMO2 binds to a partner protein nucleating further interactions and
suggests approaches for therapeutic targeting of LMO2.
T
he LIM-only family of proteins has four members (LMO1-4) and are implicated in a spectrum of cancers1,
including T cell leukaemia (LMO1, 2, 3)2–6,7, diffuse large B cell lymphoma (LMO2)8,9, prostate cancer
(LMO2)10,11, neuroblastoma (LMO1 and LMO3)12–14 and breast carcinoma (LMO4)15. LMO2 was originally
cloned from a chromosomal translocation breakpoint in T-cell acute leukaemia (T-ALL)3,5 that involved T-cell
receptor loci (either TCRd at 14q11 or TCRb 7q35 in respectively t(11;14)(p13;q11) or t(7;11)(q35;p13)) and the
LMO2 gene on chromosome 11 at band p13. Aberrant LMO2 expression is oncogenic in T cells16–18, while its
normal role is in haematopoiesis, being required for both primitive and definitive haematopoiesis19,20, as well as a
role in endothelial cell remodeling21. The LMO2 gene encodes a cysteine-rich protein, comprising two zinc-
binding LIM domains22, each with two LIM fingers, that acts as a protein binding module interacting with a
number of different proteins to form bipartite DNA-binding multi-protein complexes23.
In the normal development of T cells, LMO2 expression is down regulated during the initial stages of T-cell
development24 and is not required for normal development of this lineage25. T-ALL is characterized by an accu-
mulation of immature T-cells in the bone marrow. The effect of enforced LMO2 expression in T-cells was analysed
with a transgenic mouse model in which Lmo2 was expressed in thymocytes using the CD2 promoter. Analysis of
thymocytes from these mice showed an asymptomatic (pre-leukaemic) phase associated with an increase in the
proportion of CD4-;CD8- double negative cells18,26 with a majority block at the double negative 3 (DN3; CD44-
;CD251) stage of development preceding the appearance of clonal T cell tumours27. Transplantation studies using
the T cells from a CD2-Lmo2 transgenic mouse showed that the DN3 cells (but not DN1, DN2 or DN4) could be
transplanted into irradiated recipients and had properties of self-renewal27, further supporting the concept that the
initial function of LMO2 in T cell neoplasia is to cause a population cells (DN3) to expand as the site of secondary
mutations to cause overt neoplasia. The Lmo2-transgenic mice develop clonal thymic tumours from around 6–9
months18,26 implying that LMO2 is necessary but not sufficient for T cell neoplasia. Conversely, it was shown that
intracellular antibody fragments and peptide aptamers that interfere with LMO2 in tumour cells are effective in
suppressing tumour growth28–30, indicating that sustained expression is required to maintain T cell tumourigenesis.
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Since LMO2 functions as a transcription factor that assembles
multi-protein complexes in normal settings (e.g. erythropoiesis) or
abnormal settings (e.g. T cell cancer where chromosomal transloca-
tions cause aberrant LMO2 expression), approaches are needed to
interrogate the mechanisms by which these protein complexes form.
This will lead to an understanding of the biochemistry of this tran-
scription factor complex assembly and the controls that are exerted
in aberrant settings such as tumours and will potentially add to
understanding of how protein complexes form in normal and abnor-
mal cell metabolism. We previously compared the DNA binding
properties of the LMO2-complex in erythroid cells with an LMO2-
complex in T cell tumours from a strain of CD2-Lmo2 transgenic
mice using the CASTing methodology31. We observed that in eryth-
roid cells (a normal LMO2 expression setting) the LMO2 complex
comprised LDB1, TAL1/SCL, E47 and GATA1 with the TAL1/SCL-
E47 basic-helix-loop-helix (bHLH) heterodimer binding an E-box
DNA motif and the GATA1 protein binding the GATA site23.
Conversely, the T cell complex could comprise LMO2, LDB1 with
two TAL1/SCL-E47 heterodimers, each binding to E-boxmotifs in T
cells from Lmo2-transgenic mice32. Further binding studies with
LMO2 showed it has the capability to bind to other bHLH proteins
such as LYL1 and TAL233 both of which have been implicated in T
cell tumours34 suggesting a possible inter-connectivity of LMO2 and
bHLH proteins, dictated by aberrant expression of LMO2 in human
cancer. LMO2 is down regulated by the DN3 stage in mice18,26,27 and
evidently it is enforced expression of LMO2 that results in a block in
T-cell development.
In addition to the intricacies of the protein-protein interactions
(PPIs), a central question about LMO2 is the way in which it, and
other specific proteins, find each other in the cellular milieu and
locate the DNA binding sites. As a corollary, there are currently no
clear mechanisms that could be exploited to develop therapies based
on interfering with these LMO2-dependent PPI. The central role of
LMO2 prompted us to develop an anti-LMO2 single VH domain
intracellular antibody fragment (referred to as VH#576) to interfere
with LMO2 protein function35. Antibodies and derivative fragments
have the capacity to bind a huge variety of antigens with high spe-
cificity and affinity. Antibody binding sites comprise heavy chain
variable domain (VH) and light chain variable domains (VL), each
with three complementarity determining regions (CDRs), directly
contacting antigen and involved in binding affinity and specificity.
Single domain antibody fragments encompass a minimal antigen
recognition and can also be used for intracellular applications. The
single domain comprising specific V region framework scaffolds
have excellent properties of solubility, stability, and high expression
levels within the cell.
VH#576moderates the tumourigenic function of LMO2 in vivo as
it prevents Lmo2-dependent tumour growth in a transplantation
assay. We have determined the crystal structure of human LMO2
in complex with VH#576 at 2.9 A˚ resolution (PDB ID 4KFZ) and
found that LMO2 adopts a stable but contorted structure whose
conformation is altered around central, short alpha helical region
between the two LIM domains36. All three complementarity deter-
mining regions (CDRs) of the VH#576 are involved in direct inter-
action with LMO2. This suggests a mechanism for the normal role of
LMO2 in protein complex formation and a mechanism for the per-
turbation of LMO2 structure-function by the VH. Our work locates
specific interacting residues on the surface of both LMO2 and
VH#576 that could inform the design of small molecules to disrupt
leukaemia-associated LMO2 complexes.
Results
Interaction with the single antibody domain stabilises LMO2 struc-
ture. We previously described a single domain (VH) antibody
fragment (VH#57635), identified by the Intracellular Antibody Cap-
ture procedure37,38, that displays inhibitory function when binding to
LMO2 in T cell neoplasias or erythroid cells. As an approach to
determine the mechanism of LMO2 inhibition by VH#576, we co-
expressed LMO2 with VH#576 as a recombinant protein complex
in E. coli for structural studies. Whereas previous attempts to
make soluble LMO2 recombinant protein have been unsuccessful,
co-expression with VH#576 in E. coli drastically increases the
solubility, due in part to shielding of hydrophobic regions. Paren-
thetically, this property of single antibody domains, or scFv, to assist
in deriving soluble recombinant proteins, should be a generally
useful property for structural studies of otherwise intransigent
proteins.
Crystal trials were carried out with the purified heterodimer and
diffracting crystals were obtained (Supplementary Fig. 1). This
resulted in a 2.9 A˚ structure of human LMO2 in complex with
VH#576 (Fig. 1 and data collection statistics in Supplementary
Table 1). The architecture of VH#576 is that of the common
LMO2
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Figure 1 | Structure of the LMO2 in complex with the anti-LMO2VH#576. The crystal structure of the dimeric complex of LMO2 and anti-LMO2VH is
shown either in space filling (A) or ribbon form (B). In both, the LMO2 protein is shown in blue and the VH framework region in cyan with CDR regions
one, two and three highlighted in salmon, orange and cream respectively. In panel B, the zinc atoms are shown as grey spheres and sticks are used to
represent residues involved in inter-molecular hydrogen bonds with oxygen and nitrogen atoms coloured red and blue respectively. For VH#576, there is
one residue of CDR one (His31) forming a hydrogen bond, one in CDR two (Ser57) and four in CDR3 (Ser103, Glu105, Thr107 and Trp110).
www.nature.com/scientificreports
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immunoglobulin fold and was solved bymolecular replacement. The
LIM1 and LIM2 domains of LMO2 were positioned according to
experimentally determined zinc positions. Structure refinement
was completed using PHENIX-REFINE and AUTOBUSTER soft-
ware. The LIM1 domain of LMO2 possesses the characteristic LIM
domain structure of four b-strands and this is followed by a short a-
helix, encompassing the hinge region residue Phe8836. Each zinc
atom was positioned between a pair of anti-parallel b-strands. All
four zinc ions are present in the structure and each is coordinated in a
tetrahedral geometry by the side chains of three cysteine residues and
one histidine or aspartic acid residue. Furthermore, zinc ions are
stable in a cellular environment due to the lack of redox activity39.
LMO2 has a long N-terminal tail (residue 8–26, see Supple-
mentary Fig. 2B) with no defined secondary structure in the crystal.
The first 20 residues of LMO2 are predicted to be disordered by
regional order neural network software40. This region has a high
content of charged/hydrophilic residues and few bulky hydrophobic
residues characteristic of intrinsic disordered proteins41. The func-
tion of this N-terminal region may be in transcriptional control, as
we have shown that it can act as a transcriptional trans-activator in
two-hybrid reporter assays42.
Each of the VH#576 CDR loops is involved in the binding to
LMO2 (Fig. 1) and these span amino-acid contacts in both LIM
domains (contact residues are listed in Supplementary Table 2). In
addition, there is an interacting loop from a framework region that
binds to the LIM2 domain (Fig. 1B); this region of hydrophobic
contacts lies at the former VH-VL interface of VH#576 spanning
Val37 to Tyr50 (see Supplementary Fig. 2A). The close proximity
of residues Leu45 and Tryp47 of VH#576 to Met108 and Met106 of
Lmo2 indicate the hydrophobic effect to be a driving force in the
LMO2-VH interaction. Both the methionine residues of LMO2 are
located in the finger 3 region. Other hydrophobic amino acids inter-
actions are in finger 4 and between the zinc-coordination residues of
the second zinc atom of finger 3 (Supplementary Table 2).
The potency of interaction of the individual residues in the
VH#576 CDRs was elucidated by their mutagenesis to Gly and/or
Ala and the effect on interaction between the mutant VH#576 and
LMO2 was determined by a mammalian two-hybrid luciferase
reporter assay (Fig. 2A–C). To assess effects of the CDR mutations
on expression levels, each mutant VHmade as a fusion with VP16 at
the C-terminal and expression assessed by Western blotting using
anti-VP16 antibody (shown at the bottom of each panel of Fig. 2A–C
and in Supplementary Fig. 3 with controls of VH#576 and/or
VHY#6). These data show that residues in all three CDRs are critical
for VH binding as specific mutations ablate interaction of the VH
and LMO2 in the mammalian intracellular assay. The critical CDR
residues are indicated in Supplementary Fig. 2A. Residues of CDR3
are particularly important (8 residues in this region are hot spots)
when analysed in the two hybrid assay, as it has the highest propor-
tion of residues involved in the interaction with LMO2. This concurs
with the crystal structure (Fig. 2D, E). A hydrogen bonding network
occurs between the LIM finger three of LIM2 and CDR3 of VH#576
residues Ser103, Glu105 and Thr107 (Fig. 2E, Supplementary Table
2). Arg109, a residue that is critical in LMO2-LDB1 LID interaction,
forms a salt bridge with Glu105 of VH#576. In effect the VH#576
exploits naturally used loops (CDRs) as well as a region generally
masked byVH-VL interaction to perform its role in inhibiting LMO2
function.
LMO2 structure differs when bound to the VH or to LDB1 LID.
We generated an in silico structure of the LMO2 protein usingmouse
Lmo4 and partial mouse Lmo2 structural data43,44 that identified a
central helical region between the two LIM domains28. This included
the hinge region residue Phe88 that was identified when the structure
of LMO2 was solved in complex with LDB1-LID36. LDB1 is a widely
expressed nuclear adaptor protein that binds LMO proteins through
its C-terminal LID (LIM-interacting domain) and forms part of the
LMO2 protein complex first identified in erythroid cells23 and later
shown to be of similar composition in T cell neoplastic cells32.
Superimposition of the respective shapes of LMO2 was carried out
for our current structural analysis of LMO2-VH complex with the
LMO2:LDB1-LID fusion protein36 and using the first LIM domain of
LMO2 in both crystal structures for alignment (Fig. 3A). This shows
that the LIMdomains of both dimeric structures have close structural
similarity but the relative orientation of the LIM1 and LIM2 domain
varies markedly (Fig. 3A, B).
The LIM2 is mis-oriented compared with LMO2:LDB1-LID
allowing interactions between VH#576 and the conserved b-strand,
b7 of LMO2 (see Supplementary Fig. 2 forb strand nomenclature). In
figure 3C, hydrophobic amino acids are represented in ball and stick
form at the former VH/VL interface of anti-LMO2 and residues
Met106 and Leu117 indicating the hydrophobic contribution to
binding at the protein-protein interface. Specifically, the angle
between LIM1 and LIM2 varies by 23u between the two structures.
The zinc positions within the electron density map were located
using PHENIX AutoSol and are shown in Supplementary figure 4.
Although an angle of motion between the LIM domains of LMO2
was observed between two independently determined crystal struc-
tures of LMO2:LDB1-LID fusion protein45,36 when comparing LMO2
in complex with LID or with VH#576 an overall root mean square
deviation (RMSD) of 5.3 A˚ was calculated. The conformational
change in LMO2 bound by the VH is more profound than that
between LMO2:LDB1-LID structures where there is a maximum
overall RMSD of 2.6 A˚. In essence, VH#576 acts to contort LMO2
through a series of high affinity interactions, particularly with LIM2
of LMO2. Thus we conclude that the VH#576 interaction with
LMO2 results in contortion of the LMO2 protein because LMO2 is
highly dynamic and flexible such that its stable configuration is
dependent upon its interaction partner. This may reflect a mech-
anism of allosteric control mediating associations with a broad range
of natural protein partners.
The anti-LMO2 VH sequesters LMO2 from normal binding part-
ners in vivo.The alternative conformations that the LMO2 flexibility
allows suggests that protein-protein interactions can be influenced
by this and that themechanism bywhich the anti-LMO2VH impairs
function is by removing newly synthesized LMO2 into a separate
complex. This hypothesis was tested using transfection studies in
CHO cells that assessed individual interactions. It has been shown
that LMO2 binds directly to a number of T-ALL associated bHLH
proteins, including TAL1/SCL, TAL2 and LYL118,23. LMO2 does not
bind directly to the E2A bHLH E12 or E4733 but forms a complex
with E47 via LMO2-TAL1/SCL interaction in which the latter
hetero-dimerises with E47. Luciferase assays were performed in
CHO cells that were transfected with two LMO2 baits comprising
the Gal4DBD fused to LMO2 or the LMO2-LDB1 LID fusion and a
TAL1/SCL-VP16 fusion prey, with or without a vector expressing
E47 bHLH (Fig. 4A, B). TAL1/SCL binds to LMO2 but does so
relatively poorly compared with the LMO2-LID fusion (Fig. 4A).
In addition, the binding has more efficacy when the TAL1/SCL
partner E47 is present (Fig. 4A) although again the LMO2-LID
bait is more efficacious. Little evidence of interaction was found
with the LMO2-VH#576 when the LMO2 was expressed as the
fusion with the LDB1 LID (Fig. 4B) since the luciferase activation
was reduced to control levels (e.g. when LMO2-LID was co-
expressed with an anti-RAS VH#Y6).
Pull-down experiments were carried out to further analyse the
mutually exclusive in vivo protein binding. COS-7 cells were co-
transfected with LMO2, LDB1, TAL1, E47 and GATA-1 and
either Flag-tagged VH#576 or Flag-tagged VH#Y6 (a non-relevant
VH). Protein complexes associated with the VH proteins were
analysed by capturing protein with anti-Flag antibody beads,
www.nature.com/scientificreports
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fractionating on SDS-PAGE and Western blotting with the anti-
bodies shown in Fig. 4C. The pull-down data mirror those
obtained in the two-hybrid reporter systems since the Western
shows that expressed VH#576 associates with predominant
amounts of LMO2 (Fig. 4C), only a very small, proportional
amount of LDB1 but we could not detect associated TAL1/SCL
or GATA1 in this assay.
Finally, it does not appear that the binding of LMO2 by VH#576
simply results in removal of LMO2 by proteolysis as MEL cells
transfected with VH#576 expression vectors display approximately
similar levels of LMO2 protein as do untransfected cells (Fig. 4D).
This means that LMO2-VH complex is located in the cells as a stable
dimer that is not per se subject to increased instability. These data
support the concept that binding of LMO2 by the VH#576 limits its
natural interactions by sequestration and that LDB1 presents the
LIM domains in such a way to enable further native protein complex
assembly.
Discussion
The LMO2 gene is a paradigm of a chromosomal translocation mas-
ter gene46 as it encodes a developmental regulator whose function is
subverted by the contextual alteration of expression following
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Figure 2 | Probing the interaction surface of VH#576 with LMO2 using site directed mutagenesis. The CDR residues of VH#576 were mutated to
glycine or alanine and the mutant sequences cloned into pEF-VP16 vector (prey vector) for use in a mammalian two-hybrid luciferase reporter assay.
These assays were performed by transient transfection into CHO cells by co-transfecting the prey vector with a vector expressing a Gal4-LMO2 fusion bait
(pM1-dLMO2); luciferase signals in the histograms are the ratio of Firefly luciferase to Renilla luciferase where the latter was used as a transfection control.
Controls were performed using VH#576 (positive control) and anti-RAS VH#6 (negative control). The expression levels of eachmutant VH#576 protein
were established by Western detection with an anti-VP16 antibody (shown at the bottom of panels A, B, C). Panel A shows data for mutations of CDR1
residues, panel Bmutations of CDR2 residues and panel Cmutations of CDR3 residues. Each bar represents an average of luciferase activity measured for
twowells (replicates) and the bar extensions indicate the standard deviations. Panels D and E highlight the key residues in the VH#576 that emerged from
the mutation analysis shown in A-C. The CDR1, CDR2 and CDR3 of VH#576 are shown in salmon, orange and cream respectively. In panel D, LMO2 is
shown in yellow (space filling format) and the framework region of VH in cyan, with the indicated amino acids being from the VH. Red patches are areas
of oxygen atoms, blue are areas of nitrogen atoms. In panel E the interactions of VH#576 CDR3 are highlighted. A majority of the interactions occur
through the CDR3 region (cream) with a total of seven CDR3 residues identified as critical for the interaction. A series of interactions occur across the
hinge region (Phe88) of LMO2 including a salt bridge between Glu105 and Arg86, and polar contacts, represented by dashed lines. Zinc atoms are shown
as yellow spheres.
www.nature.com/scientificreports
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translocation to T cell receptor loci. This property, manifest in
transgenic mouse models by a blockade of differentiation of thymo-
cytes18,26, and is exerted by LMO2 mediating the formation
multi-protein DNA-binding complexes23. Our data show that the
anti-LMO2 intracellular VH antibody fragment substantially inter-
feres with the formation of this protein complex by amechanism that
does not simply involve enhanced degradation of the LMO2 protein
itself47. Rather, structural determination of LMO2 in complex with
the VH suggests a mechanism of functional inhibition whereby the
conformation of LMO2, when in complex with VH, is distinct from
that normally found and that this impairs binding of LMO2 to its
natural partners.While the first LIM domain seems to be structurally
unaltered by interaction with the VH compared to interaction with
LDB1 (Figs. 1, 3), the second LIM domain lies at an angle compared
23°
LMO2 when in complex with LID
LMO2 when in complex with VH
LDB1-LID
Anti-LMO2 VH
LIM1 LIM2
B
C
A
Trp47
Leu45
Met106
Leu117
Met 108
Phe 120
Figure 3 | Comparison of the geometry of the LMO2:VH dimer with the LMO2:LDB1-LID protein. Superimpositions are shown of LMO2 with the
LDB1 LID domain or with anti-LMO2 VH#576 and were performed using the first LIM domain for alignment. Panel A depicts the structure of LMO2 in
green (with the zinc atoms shown as green spheres) when bound to LID or in blue when bound to VH#576. Panel B shows the dimeric LMO2 structures
with LDB1-LID shown in red bound to LMO2 (green) compared with the structure of the LMO2 (shown in dark blue) complexed with the VH (shown in
cyan). The angle between LIM1 and LIM2 domains differs by 23u between the two LMO2 structures. LMO2 wraps around VH#576 and forms a
strong hydrogen bonding network including the b-strand of VH#576 typical of protein-protein interactions. The b-strands at this interaction site are
parallel and an analogous interaction occurs between b-strand 7 of LMO2 (see Supplementary fig. 2) and LDB1-LID, with LMO2 residues Thr107 and
Arg109, being key residues in both interactions. Hydrophobic amino acids at the protein-protein interface are indicated in panel C, focused around
LMO2 residues Met106, Met108, Leu117 and Phe120 with VH#576 residues Trp47 and Leu45 indicating the hyrdrophobic effect contributes to binding.
Zinc atoms are shown as green or blue spheres respectively where LMO2 interacts with LDB1 or with VH#576.
www.nature.com/scientificreports
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to LMO2-LDB1. The degree of distortion of the second LIM domain
is reminiscent of the inhibitory effect a peptide aptamer that we
discovered that also interacts with the finger 4 of LMO228. In this
case, the peptide seems to bind competitively to the fourth zinc atom.
These observations suggest that targeting this region of the LMO2
protein would be an effective drug strategy.
In normal circumstances, interaction of LMO2with LDB1 confers
a structure on LMO2 that enables the assembly of an active tran-
scription factor complex. The conserved hinge region between the
two LIM domains of LMO2 has been identified which enables inter-
action with other proteins, such as bHLH that may occur in contact
with DNA. The anti-LMO2 VH exploits this flexible region to allow
contortion of LMO2 into a conformation that impairs the binding of
natural partners such as TAL1/E47 and GATA-1, thereby inhibiting
formation of a functional transcription factor complex.
Mammalian two-hybrid data also show that VH#576 binds poorly
to LMO2:LDB1-LID (Fig. 4) and cannot compete with LDB1 for
LMO2 binding whereas LDB1 can compete VH#576 binding to
LMO235. This is consistent with the higher affinity of LDB1 than
VH#576 for LMO2 (the former being kd52.031028 M and latter
kd59.431028 M35. Therefore, inhibition of LMO2 by VH#576 pre-
sumably occurs by sequestering newly synthesized protein. Further,
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Figure 4 | Intracellular binding of anti-LMO2VH#576 to the LMO2 protein.Amammalian luciferase two hybrid assay was used to assess interactions of
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LMO2:LDB1-LID and VP16 activation domain prey plasmids expressing TAL1/SCL-VP16, VH#576-VP16 or VH#6-VP16. Where indicated, a plasmid
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control, anti-RAS VH, VH#6, panel B). (C) Western blotting of pull-down proteins. COS-7 cells were co-transfected with LMO2, LDB1, TAL1, E47 and
GATA-1 and Flag-tagged VH#576 or Flag-tagged VH#6 (a non-relevant VH). Protein complexes were isolated with anti-Flag antibody beads and purified
proteins separated on SDS-PAGE. The presence of LMO2, LDB1, GATA-1 or TAL1 was detected byWestern blotting. (D). The effect on protein stability
of binding VH#576 to LMO2 was measured using MEL585 cells stably expressing VH#576 or VH#6 (anti-RAS). Protein extracts from these or
untransfectedMEL585 (-) was separated by SDS-PAGE and transferred tomembrane forWestern analysis with anti-flagmousemonoclonal antibody (a);
anti-tubulin as a protein loading control (b); or anti-LMO2 monoclonal antibody (AbD Serotec) (c) and anti-tubulin as a protein loading control (d).
The Western blots have been cropped for clarity; please see Supplementary figures 5 and 6 for full length blots.
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the small size of LMO proteins suggests they should be capable of
freely moving between the cytoplasm and the nucleus)30,48 however
they are found predominantly in the nucleus, possibly through nuc-
lear retention by LDB1. The interaction betweenVH#576 and LMO2
may occur in the cytoplasm following protein synthesis, preventing
the interaction between LMO2 and LDB1.
These studies into anti-LMO2 VH suggest a model (Fig. 5) in
which alternative LMO2 structures dictate functional outcome.
Our studies suggest that initially synthesized LMO2 protein is
intrinsically disordered and that binding to a partner protein confers
a configuration that nucleates subsequent protein complex forma-
tion. The structure of LMO2:LDB1-LID36,49, demonstrates a rela-
tively flat, extended rod structure, able to ‘‘present’’ the LIM
fingers to allow for other protein-protein interactions such as with
GATA150. By contrast, interaction with VH confers a distinct struc-
ture that renders LMO2 inactive due to inefficient binding of natural
partners. Recent data reveal the N-terminal zinc finger of GATA1
mediates the interaction between GATA1 and LMO251. These data,
and our in silico model of the pentameric complex generated from
individual structural information (Fig. 5), indicate that a singlemole-
cule of LMO2 could bridge the DNA binding proteins GATA1 and
TAL1/SCL-E47, in keeping with our original model of the LMO2
complex23. These data suggest a model in which LMO2 binds LDB1
in the cytoplasm and is then transported to the nucleus. The LDB1
interaction ‘‘tethers’’ the LIM domains in such a confirmation to
allow TAL1/SCL-E47 to interact with the LMO2 LIM1 domain
and for GATA-1 to interact with the LIM 2 domain and also other
protein-protein interactions.
The data described in this paper have implications for both the
mechanism of LMO2 transcription factor complex formation and
how the structure of LMO2 may be exploited in a therapeutic
approach. All our previous attempts to produce recombinant
LMO2 protein have proved unsuccessful due to the intransigent
insolubility of the protein in induction systems (unpublished).
However, we found that co-expressing LMO2 with the anti-LMO2
single domain resulted in efficient production of soluble protein that
was readily purified and crystallized in the dimeric state35. This has
twomain implications. First, the use of single domain VH (or indeed
scFv) to facilitate co-expression of otherwise intransigent proteins is
likely to be a useful general strategy. Molecules like LMO2, that show
significant intrinsic flexibility52,49, could be stabilized by binding with
antibody fragments aided by the masking of hydrophobicity in the
interaction with the VH interface.
Keeping in mind that the VH#576 antibody single domain was
isolated from a diverse library of VH segments merely by its binding
property with an LMO2 bait, the mechanism of functioning is sig-
nificant. The manifest stabilization of the LMO2 structure by inter-
action with the VH#576 and the sequestration of the bound LMO2
into a state that reduces the interaction of LMO2 with its natural
partners such as LDB1 and TAL1/SCL has implications for the nat-
ural formation of the LMO2multi-protein complex. The noted hinge
region between the two LIM domains provides the motional flexibil-
ity that locks LMO2-LDB1 interactions and places LMO2 in a con-
figuration that facilitates the surrounding protein complex
formation involving variously TAL1/SCL, E47 and GATA1. This
final complexmay require contact withDNAbinding sites. In similar
vein, when the anti-LMO2 VH#576 binds to the unstructured
LMO2, the dimer complex adopts a configuration that distorts the
LMO2, particularly the LIM2 domain is bent around Phe88 and the
fourth zinc atom is misaligned from the normal context. This struc-
turally serves to sequester LMO2 protein away from the natural
complex. The LMO2-VH dimer is not wholly degraded but rather
is isolated.
The nature of the VH#576 single domain binding to LMO2 is
unusual as there is binding from framework residues (listed in
Supplementary Table 2), some of which come from former VH-VL
interface residues. The region of VH#576 binds to the LIM2 domain
of LMO2 assisting in the stable configuration of LMO2. Residues
from all three VH CDRs are involved in binding LMO2 such that
there are contacts on both LIM1 and LIM2 domains across the Phe88
Figure 5 | The sequestrationmodel for building of LMO2 protein complexes. In the structural data of this paper and previous publications, it seems that
the newly synthesized LMO2 protein (shown in green) is intrinsically unstable, with few structured regions. One structured region is the central short a-
helix between LIM1 and LIM2 domains, giving the LMO2 protein options for interacting with partner proteins.When it binds to a natural partner such as
LDB1 (shown in red), a structural constraint is imposed on LMO2 and the heterodimer can nucleate subsequent protein complex formation, depicted
here the complex found in erythroid cells including GATA1. The inhibitory effect of the VH#576 (shown in blue) exploits the LMO2 hinge region and the
unstable properties by sequestering LMO2 (shown in green) into a complex that has poor interacting properties with natural partners. TAL1/SCL is
shown in yellow, E47 in orange and GATA1 in blue. The diagrammatic model of the pentameric complex of LMO2 (green), LDB1 (red), E47 (orange),
TAL1 (yellow) and GATA-1 (blue) was generated by in silico modeling. The structure of a guide DNA including the binding motifs for E47-TAL1
(CAGGTG) and GATA-1 (GATA) transcription factors was generated using Nucleic Acid Builder of AMBER tools69. Subsequently, the structures of
GATA-1, E47 and TAL1 boundDNAwere derived by homologymodeling70 using GATA-1 (PDB codes 1gat71 and 1gnf72) and heterodimer E47/NeuroD1
transcription factor (PDB code 2ql273) structures as templates for GATA-1 and E47-TAL1 respectively. The orientation of LMO2-LDB1 was manually
adjusted by maximizing the overlap of interactions regions described in the literature: LMO2-E47-TAL136 and LMO2-GATA-174.
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hinge. The imposition of this ‘four-handed’ binding by VH#576 is
sufficient to impose functional ablation by sequestration.
VH#576 is a macromolecule that could be used as a drug per se if
methods for efficient delivery into cells in vivo can be achieved53.
There are several options whereby this might be achievable for the
use of macromolecules as drugs (macrodrugs)54. The use of chemical
emulators of macrodrug binding is an enticing, but not yet achieved
goal, of this field of work. It has been thought that obtaining small
molecule drugs that prevent protein-protein interaction would not
be possible but more examples of this are becoming known55. One
issue will be the relatively low affinity that can be achieved with a
small molecule to bind at a PPI interface and prevent interaction of
two larger proteins. Our findings with the LMO2-VH#576 complex
offers an possible strategy that would be based on obtaining two
compounds to emulate, respectively, the binding sites of VH#576
on LIM1 and LIM2. If these can be isolated and chemically joined56,
the affinity of the final compound would be the product of the two
affinities, potentially giving a high affinity compound that can emu-
late the LMO2 bending and effective inactivation.
Methods
Protein expression and purification. For co-expression of recombinant LMO2 and
the anti-LMO2 VH576 single domain, an initial bicistronic expression vector (pRK-
HIS-TEV-VH576-LMO2) was constructed by sub-cloning the anti-LMO2 VH#576
in-frame35. Truncated LMO2 (LMO2D8ND11C residues 9–147) cDNA was used to
replace LMO2 in the pRK-HIS-TEV-VH576-LMO2 construct using restriction
enzyme sites NheI and EcoRI. pRK-HIS-TEV-VH576-LMO2 was subsequently
engineered to create expression vector pRK-HIS-TEV-VH576-LMO2 (LMO2D8N
residues 9-158). The construct was transformed into E. coliC41(DE3) and cultured in
1 L of LB plus ampicillin (100 mg/ml) at 37uC, aerated at 225 rpm until the
absorbance at 600 nm reached 0.6. ZnSO4 was added prior to induction to a final
concentration of 0.1 mM. Protein expression was induced by adding Isopropyl b-D-
1-thiogalactopyranoside to a final concentration of 0.5 mM, and incubated at 16uC
for 14 hours. TheVH#576-LMO2protein complex was extracted after cell disruption
(Constant cell disruption system) in 20 mM Tris-HCl pH 8, 250 mM NaCl, 20 mM
imidazole, 0.1 mM ZnSO4, 10 mM b-mercaptoethanol and EDTA-free protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). LMO2 and VH#576
were co-purified using a Ni21 charged HiTrap chelating HP column (5 ml, GE
Healthcare) using a gradient elution from 20 to 300 mM imidazole. To remove His-
tag from VH#576, the purified proteins were digested with his-tagged Tobacco Etch
virus protease at 4uC overnight during dialysis against the buffer without imidazole.
The proteins were passed through a nickel-nitrilotriacetic acid agarose column
(Qiagen), the bound material eluted and concentrated using an Amicon Ultra-15
centrifugal filter device, 10 KDa cut-off (Millipore, MA, USA). For further
purification of LMO2-VH#576 complex, the proteins were size-excluded by gel
filtration chromatography with a Hi-Load Superdex 75 column (GE Healthcare,
Uppsala, Sweden) in 20 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM DTT. Fractions
containing VH#576/LMO2 complex were pooled and concentrated to 8 mg/ml and
used for crystallisation (Supplementary Fig. 1A).
Crystallization and structure determination of LMO2 in complex with VH#576.
VH#576-LMO2D8ND11C was crystallised using the sitting-drop vapour-diffusion
method at 294 K. Precipitant solutions (100 ml per well) were dispensed into
reservoirs of a Greiner 96 well plate. Using a robot (Cartesian) 100 nl from each
reservoir was dispensed onto each platform along with 100 nl of protein to form a
single droplet. Each plate was sealed manually, using self adhesive transparent film
(Viewseal, Greiner). Crystals appeared after a day and further optimization was
performed in 24-well Cryschem plates (Hampton Research, CA, USA), mixing 2 ml
protein solution with 1 ml reservoir solution and equilibrating the drop against
500 ml reservoir solution. The best diffracting crystals grew within one week of setup
in 100 mM MES monohydrate pH 6.0, 0.8 M ammonium sulfate, and additive 1, 6
hexanediol. Crystals typically measured 100 mm by 40 mm (Supplementary Fig. 1B).
For data collection, the crystals were flash-cooled to 100 K in a cryo-protectant
solution consisting of mother liquor and 30% glycerol. A three wavelengths MAD
data set was collected on the Zn K-edge using an ADSC Q315 detector on beamline
I02 at the Diamond Light Source (Didcot, UK). Analysis of the diffraction data using
HKL200057 showed that the crystals belonged to space group P6 (unit cell dimensions
a, b5124.3, c581.4 A˚ and a, b590.0u, c5120.0u) with two molecules in the asym-
metric unit (Matthews coefficient,VM5 2.87 A˚3/Da21 with a solvent content of 57%58.
The structure of VH#576/LMO2 was solved by a combination of molecular
replacement and SAD phasing. A molecular replacement solution for the VH#576
was determined with the program PHASER59 using the anti-RASVH#Y6 heavy chain
as a search model (PDB 2UZI). PHENIX AUTOSOL60 was used to locate the LMO2
intrinsic zinc positions using a three-wavelength anomalous dispersion experiment at
the peak, inflection and remote wavelengths of the Zn X-ray absorption edge. The
molecular replacement program MOLREP61 was used to search within this map for
two LIM1 domains (using the isolated LIM1 from LMO2:LDB1-LID as a search
model (PDB 2XJY)36 and successfully positioned the two molecules. The LIM2
domain (from LMO2:LDB1-LID) was manually positioned in the electron density
map using the determined PHENIX zinc positions as anchor points. Manual model
building of the structure was done using the COOT (Crystallographic Object-
Oriented Toolkit) software62 and restrained refinement was performed with
PHENIX-REFINE and then AUTOBUSTER63,64 taking care of keeping the same Rfree
test set in both programs. Non-crystallographic symmetry (NCS) restrains were
imposed on the 2 VH#576/LMO2 heterodimers. Towards the end of refinement, TLS
(Translation/Libration/Screw) vibrational motion refinement was used. At a later
date diffraction data was collected from crystals made up of VH#576-LMO2D8N,
formed using the same conditions. Data was processed and refined to give a final
Rwork/Rfree of 23.9/25.8%. Refinement statistics are listed in Supplementary Table I.
Mutation of the anti-LMO2 VH and mammalian two-hybrid analysis. Transient
mammalian two-hybrid assays were carried out as described elsewhere65. Selected
residues in the CDR regions of VH#576 were mutated, from the base vector template
pEF-VH#576-VP16 to either glycine or alanine by point mutation followed by
assembly PCR. The final PCR product was cloned back into pEF-VP16 using SfiI and
NotI as a fusionwith theVP16 activation domain. Truncated LMO2 bait (amino acids
28-150, see Supplementary Fig. 2) was cloned into the pM3 vector66 as a fusion with
theGAL4DNA-binding domain. CHO cells were co-transfected using Lipofectamine
2000 (Invitrogen) as previously described67 with appropriate plasmids pM-LMO2
bait, pEFVP16-prey, pG5-Fluc, and pRL-CML. Forty-eight hours after transfection,
the cells were lysed and assayed with the Dual-Luciferase reporter assay system
(Promega) according to the manufacturer’s instructions. All luminescence values by
firefly luciferase were normalized using Renilla luciferase levels. Expression of
VH#576 was analysed by Western blotting using anti-VP16 antibody, (14–5 Santa
Cruz biotechnology).
An LMO2-LDB1-LID construct wasmade as a fusion encoding LMO2 (residues 26
to 156) fused to LDB1-LID domain residues 336 to 368; the LMO2 was coupled C-
terminally to LID via a ten residue linker (GSGGSGGSGG). The insert was amplified
by PCR from pGBT9-LMO2:LDB1-LID (a kind gift from Dr Jacqueline Matthews)
and cloned into SalI/NotI sites of pM3. To compare the interaction between LMO2 or
LMO2:LDB1-LID with TAL1 or VH#576, pM3-bait (pM3-LMO2 or pM3-LDB1-
LID:LMO2), pEF-VP16-prey (pEF-TAL1-VP16, pEF-VH#576-VP16 or pEF-VH#6-
VP16), pG5-luc, pEF-BOS-E4723 and pRL-CML plasmids were transiently co-
transfected into COS-7 cells using Lipofectamine 2000 (Invitrogen). Forty-eight
hours post-transfection, Firefly and Renilla luciferase enzyme activities were assayed
with the Dual-Luciferase reporter assay system.
Transfection of MEL cells with VH#576. pFUW-3XFlag-VH576-GFP and pFUW-
3XFlag-VHY6-GFP vectors were prepared through a series of sub-cloning steps.
Assembly PCR was used to generate BamHI-P2A-AgeI-GFP-NheI-STOP-EcoRI.
The final PCR product was digested with BamHI-EcoRI and cloned into the same
sites of the parent vector pFUW68 3XFlag-VH#576 or 3XFlag-VH#Y6 were amplified
and the PCR products were cloned into restriction enzyme sites SalI and XbaI. The
vectors expressing the Flag-tagged anti-LMO2 VH#576 or anti-RAS VH#Y6 into
murine erythroleukaemia MEL(585) cells were transiently transfected using an
Amaxa NucleofectorTM apparatus (Amaxa), according to the manufacturer’s
instructions. 13107 cells were re-suspended in the specified Amaxa electroporation
buffer (buffer R) plus 5 mg of the plasmid. GFP-positive cells were separated by
sorting using Cytomation MOFLOW cytometer 24 hours after transfection. Equal
number of cells were lysed by 30minute incubation on ice with RIPA buffer (150 mM
sodium chloride 1.0%NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mMTris, pH
8.0) and equivalent amounts of protein extracts were separated by SDS-PAGE prior to
transfer to membranes. Western analysis used anti-FLAG (clone M2, Sigma catalog
number F3165), anti-LMO2 (clone 1A9-1, AbD SeroTec) or anti-tubulin (clone
AA13, Sigma).
Pull-down with anti-Flag beads. COS-7 cells were seeded in a 12 well plate and
co-transfected, using Lipofectamine 2000 (Invitrogen) with pGL3-ElbLUC-(Ebox-
GATA)2, pEF-LDB1, pEF-LMO2, pEF-TAL1, pEF-E47, and either pEF-3XFLAG-
VH576-NLS-neo or pEF-3XFLAG-VHY6-NLS-neo. Each transfection was done in
triplicate. Forty-eight hours post-transfection, cells were removed from the wells
using trypsin and triplicate wells pooled. Cells were pelleted by centrifugation at
1000Xg for 5 minutes and the supernatant removed. The cells were re-suspended in
200 ml lysis buffer (50 mMTrisHCL, pH7.4, 150 mMNaCl, 1 mMEDTA, 1%Triton
100, protease inhibitor) and rotated at 4uC for 30minutes. Samples were spun down at
12,000Xg for 10minutes. The supernatant removed and saved for the next step. Anti-
Flag antibody beads (Sigma, A2220) were washed and re-suspended in PBS at a ratio
of 152. 30 ml of re-suspended resin was added to each sample and rotated for 2 hours
at 4uC. Samples were spun down at 5000Xg for 5 minutes and the supernatant
removed for analysis. Anti-Flag beads were washed three times in 1 ml of PBS
followed each time by spinning down at 5000Xg for 5 minutes and removing the
supernatant. The beads were finally suspended in 90 ml of PBS and analysed by
Western blotting.
The crystal structure of LMO2 with the anti-LMO2 VH has been deposited in the
protein database with PDB ID code 4KFZ.
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